1
|
Saha SK, Zhu Y, Murray P, Madden L. Future proofing of chondroitin sulphate production: Importance of sustainability and quality for the end-applications. Int J Biol Macromol 2024; 267:131577. [PMID: 38615853 DOI: 10.1016/j.ijbiomac.2024.131577] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2024] [Revised: 04/10/2024] [Accepted: 04/11/2024] [Indexed: 04/16/2024]
Abstract
Chondroitin sulphates (CSs) are the most well-known glycosaminoglycans (GAGs) found in any living organism, from microorganisms to invertebrates and vertebrates (including humans), and provide several health benefits. The applications of CSs are numerous including tissue engineering, osteoarthritis treatment, antiviral, cosmetics, and skincare applications. The current commercial production of CSs mostly uses animal, bovine, porcine, and avian tissues as well as marine organisms, marine mammals, sharks, and other fish. The production process consists of tissue hydrolysis, protein removal, and purification using various methods. Mostly, these are chemical-dependent and are complex, multi-step processes. There is a developing trend for abandonment of harsh extraction chemicals and their substitution with different green-extraction technologies, however, these are still in their infancy. The quality of CSs is the first and foremost requirement for end-applications and is dependent on the extraction and purification methodologies used. The final products will show different bio-functional properties, depending on their origin and production methodology. This is a comprehensive review of the characteristics, properties, uses, sources, and extraction methods of CSs. This review emphasises the need for extraction and purification processes to be environmentally friendly and gentle, followed by product analysis and quality control to ensure the expected bioactivity of CSs.
Collapse
Affiliation(s)
- Sushanta Kumar Saha
- Shannon Applied Biotechnology Centre, LIFE Health and Biosciences Research Institute, Technological University of the Shannon: Midlands Midwest, Moylish Park, Limerick V94 E8YF, Ireland.
| | - Yin Zhu
- Shannon Applied Biotechnology Centre, LIFE Health and Biosciences Research Institute, Technological University of the Shannon: Midlands Midwest, Moylish Park, Limerick V94 E8YF, Ireland
| | - Patrick Murray
- Shannon Applied Biotechnology Centre, LIFE Health and Biosciences Research Institute, Technological University of the Shannon: Midlands Midwest, Moylish Park, Limerick V94 E8YF, Ireland
| | - Lena Madden
- Shannon Applied Biotechnology Centre, LIFE Health and Biosciences Research Institute, Technological University of the Shannon: Midlands Midwest, Moylish Park, Limerick V94 E8YF, Ireland
| |
Collapse
|
2
|
Inokuma K, Sasaki D, Kurata K, Ichikawa M, Otsuka Y, Kondo A. Sulfated and non-sulfated chondroitin affect the composition and metabolism of human colonic microbiota simulated in an in vitro fermentation system. Sci Rep 2023; 13:12313. [PMID: 37516730 PMCID: PMC10387111 DOI: 10.1038/s41598-023-38849-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2023] [Accepted: 07/16/2023] [Indexed: 07/31/2023] Open
Abstract
Chondroitin sulfate (CS) is a family of glycosaminoglycans and have a wide range of applications in dietary supplements and pharmaceutical drugs. In this study, we evaluated the effects of several types of CS, differing in their sulfated positions, on the human colonic microbiota and their metabolites. CS (CSA, CSC, and CSE) and non-sulfated chondroitin (CH) were added into an in vitro human colonic microbiota model with fecal samples from 10 healthy individuals. CS addition showed a tendency to increase the relative abundance of Bacteroides, Eubacterium, and Faecalibacterium, and CSC and CSE addition significantly increased the total number of eubacteria in the culture of the Kobe University Human Intestinal Microbiota Model. CSE addition also resulted in a significant increase in short-chain fatty acid (SCFA) levels. Furthermore, addition with CSC and CSE increased the levels of a wide range of metabolites including lysine, ornithine, and Ile-Pro-Pro, which could have beneficial effects on the host. However, significant increases in the total number of eubacteria, relative abundance of Bacteroides, and SCFA levels were also observed after addition with CH, and the trends in the effects of CH addition on metabolite concentrations were identical to those of CSC and CSE addition. These results provide novel insight into the contribution of the colonic microbiota to the beneficial effects of dietary CS.
Collapse
Affiliation(s)
- Kentaro Inokuma
- Graduate School of Science, Technology and Innovation, Kobe University, 1-1 Rokkodai-cho, Nada-ku, Kobe, 657-8501, Japan
| | - Daisuke Sasaki
- Graduate School of Science, Technology and Innovation, Kobe University, 1-1 Rokkodai-cho, Nada-ku, Kobe, 657-8501, Japan
| | - Kaoru Kurata
- Glycoscience, Central Research Laboratory, Seikagaku Corporation, 3-1253, Tateno, Higashiyamato, Tokyo, 207-0021, Japan
| | - Megumi Ichikawa
- Glycoscience, Central Research Laboratory, Seikagaku Corporation, 3-1253, Tateno, Higashiyamato, Tokyo, 207-0021, Japan
| | - Yuya Otsuka
- Glycoscience, Central Research Laboratory, Seikagaku Corporation, 3-1253, Tateno, Higashiyamato, Tokyo, 207-0021, Japan
| | - Akihiko Kondo
- Graduate School of Science, Technology and Innovation, Kobe University, 1-1 Rokkodai-cho, Nada-ku, Kobe, 657-8501, Japan.
- Biomass Engineering Program, RIKEN, 1-7-22 Suehiro-Cho, Tsurumi-ku, Yokohama, Kanagawa, 230-0045, Japan.
| |
Collapse
|
3
|
Sarvilina IV, Danilov AB, Tkacheva ON, Gromova OA, Solovieva EY, Dudinskaya EN, Rozanov AV, Kartashova EA. [Influence of chronic pain in osteoarthritis on the risk of cardiovascular diseases and modern methods of drug prevention]. Zh Nevrol Psikhiatr Im S S Korsakova 2023; 123:20-30. [PMID: 37315238 DOI: 10.17116/jnevro202312305120] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/16/2023]
Abstract
The purpose of the review of scientific medical literature was to evaluate the data of the epidemiology of osteoarthritis (OA) and cardiovascular diseases (CVD) with the analysis of risk factors, pathophysiological and pathobiochemical mechanisms of the relationship between OA and the risk of developing CVD in the presence of chronic pain, modern strategies for screening and management of this cohort of patients, the mechanism of action and pharmacological effects of chondroitin sulfate (CS). Conclusions were drawn about the need for additional clinical and observational studies of the efficacy and safety of the parenteral form of CS (Chondroguard) in patients with chronic pain in OA and CVD, improvement of clinical recommendations for the treatment of chronic pain in patients with OA and cardiovascular risk, with special attention to interventions that eliminate mobility restrictions in patients and the inclusion of basic and adjuvant therapy with DMOADs to achieve the goals of multipurpose monotherapy in patients with contraindications to standard therapy drugs.
Collapse
Affiliation(s)
- I V Sarvilina
- Medical Center «Novomedicina» LLC, Rostov-on-Don, Russia
| | - Al B Danilov
- Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia
| | - O N Tkacheva
- Russian Clinical and Research Center of Gerontology - Pirogov Russian National Research Medical University, Moscow, Russia
| | - O A Gromova
- Federal Research Center «Computer Science and Control», Moscow, Russia
| | - E Yu Solovieva
- Pirogov Russian National Research Medical University, Moscow, Russia
| | - E N Dudinskaya
- Russian Clinical and Research Center of Gerontology - Pirogov Russian National Research Medical University, Moscow, Russia
| | - A V Rozanov
- Russian Clinical and Research Center of Gerontology - Pirogov Russian National Research Medical University, Moscow, Russia
| | | |
Collapse
|
4
|
Shavlovskaya OA. Chondroitin sulfate in therapy osteoarthritis chronic pain patients according to actual clinical recommendations. TERAPEVT ARKH 2022; 93:1551-1555. [DOI: 10.26442/00403660.2021.12.201241] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2022] [Accepted: 01/16/2022] [Indexed: 11/22/2022]
Abstract
Of undoubted interest is the search for new drugs comparable in effectiveness to nonsteroidal anti-inflammatory drugs (NSAIDs), but with a safer application profile. NSAIDs are characterized by a good analgesic effect due to the modulation of prostaglandin metabolism by inhibition of cyclooxygenase-2. One of the promising directions of pharmacotherapy of degenerative-dystrophic joint lesions is the use of symptom-modifying drugs of delayed action, which include chondroitin sulfate (CS). CS has antiresorptive activity, anti-inflammatory and anti-inflamaging effects. In addition to the direct effect on pain syndrome severity, he also have a modulating level effect of systemic inflammation of cartilage tissue. According to experts of international and Russian societies, pharmaceutical prescription-quality CS is a basic part of the treatment of osteoarthritis. One of the advantages of CS over NSAIDs is the preservation of the effect for 24 months after the treatment. Against the background of the use of CS, it is possible to reduce the dose or completely cancel NSAIDs, which helps to reduce the frequency of adverse events associated with their intake. CS has a favorable safety profile, which is important for elderly patients and those with comorbid diseases (cardioprotective effects). CS drugs can be administered per orally, intramuscularly, intra-articularly and in combination with different administration methods. Several clinical trials of CS (Chondrogard), including randomized, were conducted in Russia. The Russia Health Ministry approved the appointment of parenteral CS in clinical guidelines: Chronic pain in elderly and senile patients (2020), Falls in elderly and senile patients(2020), "Knee osteoarthritis" (2021), "Hip osteoarthritis" (2021).
Collapse
|
5
|
Shavlovskaya O. SYSADOA place in degenerative-dystrophic joints diseases treatment of neurological practice from the standpoint of evidence-based medicine. Zh Nevrol Psikhiatr Im S S Korsakova 2022; 122:38-45. [DOI: 10.17116/jnevro202212203138] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
|
6
|
Mazzucchelli R, Rodríguez-Martín S, Crespí-Villarías N, García-Vadillo A, Gil M, Izquierdo-Esteban L, Rodríguez-Miguel A, Barreira-Hernández D, Fernández-Antón E, García-Lledó A, Pascual A, Vitaloni M, Vergés J, de Abajo FJ. Risk of ischaemic stroke among new users of glucosamine and chondroitin sulphate: a nested case–control study. Ther Adv Musculoskelet Dis 2022; 14:1759720X221113937. [PMID: 35923649 PMCID: PMC9340380 DOI: 10.1177/1759720x221113937] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2022] [Accepted: 06/08/2022] [Indexed: 11/18/2022] Open
Abstract
Background: Several studies have reported that the use of chondroitin sulphate (CS) and
glucosamine may reduce the risk of acute myocardial infarction. Although it
is thought that this potential benefit could be extended to ischaemic stroke
(IS), the evidence is scarce. Objective: To test the hypothesis that the use of prescription glucosamine or CS reduces
the risk of IS. Design: Case–control study nested in an open cohort. Methods: Patients aged 40–99 years registered in a Spanish primary healthcare database
(BIFAP) during the 2002–2015 study period. From this cohort, we identified
incident cases of IS, applying a case-finding algorithm and specific
validation procedures, and randomly sampled five controls per case,
individually matched with cases by exact age, gender and index date.
Adjusted odds ratios (AORs) and 95% confidence interval (CI) were computed
through a conditional logistic regression. Only new users of glucosamine or
CS were considered. Results: A total of 13,952 incident cases of IS and 69,199 controls were included. Of
them, 106 cases (0.76%) and 803 controls (1.16%) were current users of
glucosamine or CS at index date, yielding an AOR of 0.66 (95% CI: 0.54–0.82)
(for glucosamine, AOR: 0.55; 95% CI: 0.39–0.77; and for CS, AOR: 0.77; 95%
CI: 0.60–0.99). The reduced risk among current users was observed in both
sexes (men, AOR: 0.69; 95% CI: 0.49–0.98; women, AOR: 0.65; 95% CI:
0.50–0.85), in individuals above and below 70 years of age (AOR: 0.69; 95%
CI: 0.53–0.89 and AOR: 0.59; 95% CI: 0.41–0.85, respectively), in
individuals with vascular risk factors (AOR: 0.53; 95% CI: 0.39–0.74) and
among current/recent users of nonsteroidal anti-inflammatory drugs (NSAIDs)
(AOR: 0.71; 95% CI: 0.55–0.92). Regarding duration, the reduced risk was
observed in short-term users (<365 days, AOR: 0.61; 95% CI: 0.48–0.78)
while faded and became nonsignificant in long-term users (>364 days AOR:
0.86; 95% CI: 0.57–1.31). Conclusions: Our results support a protective effect of prescription CS and glucosamine in
IS, which was observed even in patients at vascular risk. Mini abstract Our aim was to analyse whether the use of glucosamine or chondroitin sulphate
(CS) reduces the risk of ischaemic stroke (IS). We detected a significant
decrease.
Collapse
Affiliation(s)
- Ramón Mazzucchelli
- Rheumatology Unit, Hospital Universitario Fundación Alcorcón, Alcorcón, Spain
| | - Sara Rodríguez-Martín
- Clinical Pharmacology Unit, University Hospital Príncipe de Asturias, Alcalá de Henares, Spain
- Department of Biomedical Sciences (Pharmacology), School of Medicine and Health Sciences, University of Alcalá (IRYCIS), Alcalá de Henares, Spain
| | | | | | - Miguel Gil
- Division of Pharmacoepidemiology and Pharmacovigilance, Spanish Agency of Medicines and Medical Devices (AEMPS), Madrid, Spain
| | - Laura Izquierdo-Esteban
- Stroke Unit, Department of Neurology, University Hospital Príncipe de Asturias, Alcalá de Henares, Spain
| | - Antonio Rodríguez-Miguel
- Clinical Pharmacology Unit, University Hospital Príncipe de Asturias, Alcalá de Henares, Spain
- Department of Biomedical Sciences (Pharmacology), School of Medicine and Health Sciences, University of Alcalá (IRYCIS), Alcalá de Henares, Spain
| | - Diana Barreira-Hernández
- Clinical Pharmacology Unit, University Hospital Príncipe de Asturias, Alcalá de Henares, Spain
- Department of Biomedical Sciences (Pharmacology), School of Medicine and Health Sciences, University of Alcalá (IRYCIS), Alcalá de Henares, Spain
| | - Encarnación Fernández-Antón
- Clinical Pharmacology Unit, University Hospital Príncipe de Asturias, Alcalá de Henares, Spain
- Department of Biomedical Sciences (Pharmacology), School of Medicine and Health Sciences, University of Alcalá (IRYCIS), Alcalá de Henares, Spain
| | - Alberto García-Lledó
- Department of Cardiology, University Hospital Príncipe de Asturias, Alcalá de Henares, Spain
- Department of Medicine, University of Alcalá, Alcalá de Henares, Spain
| | - Aina Pascual
- OAFI (OsteoArthritis Foundation International), Barcelona, Spain
| | | | - Josep Vergés
- OAFI (OsteoArthritis Foundation International), Barcelona, Spain
| | - Francisco J. de Abajo
- Clinical Pharmacology Unit, University Hospital Príncipe de Asturias, Alcalá de Henares, Spain Department of Biomedical Sciences (Pharmacology), School of Medicine and Health Sciences, University of Alcalá (IRYCIS), Ctra. Madrid-Barcelona, km 33,5, Alcalá de Henares 28805, Madrid, Spain
| |
Collapse
|